Enhertu demonstrates durable response in patients across HER2 expressing advanced solid tumors

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.

June 14, 2024

Vol.50 No.24

Clinical Roundup

USP1 inhibitor combination shows manageable safety profile, anti-tumor activity in metastatic solid tumors in phase I study preliminary data

Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.

June 07, 2024

Vol.50 No.23

Drugs & Targets

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

FDA granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.

April 12, 2024

Vol.50 No.15

Drugs & Targets

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

Ipsen and Sutro Biopharma formed an exclusive global licensing agreement for STRO-003, an antibody-drug conjugate in the final stages of preclinical development which targets the ROR1 tumor antigen which is known to be overexpressed in many different cancer types including solid tumors and hematological malignancies.

April 05, 2024

Vol.50 No.14

Drugs & Targets

FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors

FDA has accepted the supplemental New Drug Application for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.

February 16, 2024

Vol.50 No.07

Clinical Roundup

Wistar study finds that common cholesterol drug enhances cell-based therapy

A team of Wistar researchers led by Hildegund C.J. Ertl—a professor in The Wistar Institute’s Vaccine & Immunotherapy Center—has demonstrated that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors. The study was published in Molecular Therapy Oncolytics.

December 15, 2023

Vol.49 No.46

Enhertu demonstrates durable response in patients across HER2 expressing advanced solid tumors

YOU MAY BE INTERESTED IN

FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors

USP1 inhibitor combination shows manageable safety profile, anti-tumor activity in metastatic solid tumors in phase I study preliminary data

FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors

Ipsen and Sutro Biopharma form global licensing deal for an ADC targeting solid tumors

FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors

Wistar study finds that common cholesterol drug enhances cell-based therapy

Renew today!

Subscriber content

Login